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The use of error-prone PCR in the development of mutants could allow the obtention 
of efficient therapeutic enzymes for the treatment of infections of P. aeruginosa in 
cystic fibrosis patients.
OBJECTIVES
v Selection of the 4 candidates with more effect in PA biofilm disruption.
v Generation of enzymatic mutants with enhanced stability, specificity and biofilm
disruption activity.




1. SELECTION OF ENZYMATIC CANDIDATES. Enzyme
candidates will be incubated with PAO1 biofilms. Biofilm disruption will
be assessed by Laser Confocal Scanning Microscopy (LCSM). Elastin
production will be quantified by Elastin Congo-Red (ECR) assay.
Pyocyanin production will be quantified by spectrophotometry. The 4
candidates with higher efficiency will be selected.
3. MUTANT SCREENING. Transformants will be selected in LB agar plates
supplemented with kanamycin. Mutants will be transferred in 96-well plates with LB
supplemented with kanamycin, where protein production will be induced by adding
IPTG. Cell lysis will be performed by sonication, and the cell lysate will be added to 96
well-plates with PAO1 biofilms. Biofilm disruption will be analysed by LCSM.
2. MUTANT GENERATION. Mutants will be generated by Error-Prone
PCR using the DNA polymerase Mutanzyme II. PCR products will be cloned
in a pET-28 vector, previously digested. The construction will be transferred
by electroporation to Escherichia coli BL21 (DE3) strain its expression. 4. PURIFICATION, SELECTION ANALYSIS AND IN VIVO STUDIES.
Selected mutants will be recombinantly produced in E. col BL21 (DE3) and purified
by Ni-NTA affinity chromatography. PCN quantification, LCSM analysis and ECR
assay will be repeated. PAO1 infected Cftrtm1Unc Tg(FABPCFTR)1Jaw/J mice will be
exposed to purified enzymes. Bronchoalveolar lavage (BAL), bacterial quantification
(BQ) and lung histopathologic (LH) studies will be performed.
EXPECTED RESULTS AND PERSPECTIVES
DISSEMINATION PLAN
REFERENCES
Cystic fibrosis (CF) affects more than 80.000 people around the world.
Pseudomonas aeruginosa (PA) is the most prevalent and common
bacteria causing infections in CF patients1 and it is difficult to eradicate
due to the formation of biofilms that enhance antimicrobial tolerance2.
A large number of enzymes with biofilm disruptive activity have been
identified3. Despite that, most of them present low stability and not
enough disruptive capacity to be applied as a treatment. Thus, directed
evolution is an interesting approach to obtain efficient therapeutic
enzymes to treat PA infections in CF patients.
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v Publications in scientific journals focused on microbiology, nosocomial
infections and molecular biology.
v Results presentation in national and international conferences such as the
annual congress of the Sociedad Española de la Fibrosis Cística.v Enzymes with higher stability and enhanced antibiofilm activity.
v Reduction on the pyocyanin and elastase production less virulence.
v Biofilms with higher sensibility to antibiotics.
v Reduction of Pseudomonas aeruginosa infection in Cftrtm1Unc Tg
(FABPCFTR) 1Jaw /J mice test group.
v Future use as therapeutic enzymes and/or coatings in medical
equipment.
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Figure 1. Representation of the enzymatic selection.
Figure 2. Representation of the process of mutant generation.
Figure 4 . Diagram of in vivo studies.
Figure 3. Diagram of the screening process.
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